索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]文凤,赵健.秋水仙碱治疗冠状动脉粥样硬化性心脏病的研究进展[J].国际心血管病杂志,2024,06:329-333.
点击复制

秋水仙碱治疗冠状动脉粥样硬化性心脏病的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年06期
页码:
329-333
栏目:
综述
出版日期:
2024-12-10

文章信息/Info

Title:
-
作者:
文凤; 赵健
200003 上海，海军军医大学第二附属医院心血管内科
Author(s):
-
关键词:
秋水仙碱; 冠状动脉粥样硬化性心脏病; 中性粒细胞
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.06.001
文献标识码:
-
摘要:
炎症反应参与冠状动脉粥样硬化的产生与进展，抗炎治疗成为冠状动脉粥样硬化性心脏病（冠心病）的新兴疗法。秋水仙碱通过抑制中性粒细胞等多种机制发挥抗炎作用，可降低冠心病患者主要不良心血管事件的发生风险，尤其是慢性冠脉综合征患者，但其对急性冠脉综合征的治疗效果尚不确定，未来还需要进一步研究。该文介绍秋水仙碱治疗冠心病的临床和基础研究进展。
Abstract:
-

参考文献/References

[1] 中国心血管健康与疾病报告编写组. 《中国心血管健康与疾病报告2022》概要[J]. 中国介入心脏病学杂志, 2023, 31(7):485-508.
[2] Weber C, Habenicht AJR, von Hundelshausen P. Novel mechanisms and therapeutic targets in atherosclerosis:inflammation and beyond[J]. Eur Heart J, 2023, 44(29):2672-2681.
[3] 余淼, 杨芬, 程翔. 冠心病的抗炎治疗: 路在脚下[J]. 中华心血管病杂志, 2024, 52(6):585-588.
[4] Han TL, Tang HF, Lin CP, et al. Extracellular traps and the role in thrombosis[J]. Front Cardiovasc Med, 2022, 9:951670.
[5] Quillard T, Araújo HA, Franck G, et al. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment:implications for superficial erosion[J]. Eur Heart J, 2015, 36(22):1394-1404.
[6] Pluta K, Por?bska K, Urbanowicz T, et al. Platelet-leucocyte aggregates as novel biomarkers in cardiovascular diseases[J]. Biology (Basel), 2022, 11(2):224.
[7] Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J]. N Engl J Med, 2017, 377(12):1119-1131.
[8] Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial[J]. Lancet, 2018, 391(10118):319-328.
[9] Shah B, Allen N, Harchandani B, et al. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a pilot study in healthy subjects[J]. Inflammation, 2016, 39(1):182-189.
[10] Yuan X, Sheng L, Shi G, et al. Colchicine alleviates rosacea by inhibiting neutrophil inflammation activated by the TLR2 pathway[J]. Inflammation, 2024, 47(3):1002-1014.
[11] Li YW, Chen SX, Yang Y, et al. Colchicine inhibits NETs and alleviates cardiac remodeling after acute myocardial infarction[J]. Cardiovasc Drugs Ther, 2024, 38(1):31-41.
[12] Liu YS, Yang H, Zhu F, et al. Inhibition of STAT3 phosphorylation by colchicine regulates NLRP3 activation to alleviate sepsis-induced acute lung injury[J]. Inflammopharmacology, 2023, 31(4):2007-2021.
[13] Wróbel-Nowicka K, Wojciechowska C, Jache? W, et al. The role of oxidative stress and inflammatory parameters in heart failure[J]. Medicina (Kaunas), 2024, 60(5):760.
[14] 陈广, 李彬, 文英, 等. 秋水仙碱对心肌梗死后大鼠预后的影响[J]. 医学研究杂志, 2024, 53(1):102-106, 130.
[15] 鲁晓娜, 陈云云, 孟琰, 等. 橙皮素和秋水仙碱对心肌梗死大鼠心肌纤维化的影响[J]. 西北药学杂志, 2022, 37(5):76-80.
[16] Aimo A, Martinez-Falguera D, Barison A, et al. Colchicine added to standard therapy further reduces fibrosis in pigs with myocardial infarction[J]. J Cardiovasc Med (Hagerstown), 2023, 24(11):840-846.
[17] Akodad M, Fauconnier J, Sicard P, et al. Interest of colchicine in the treatment of acute myocardial infarct responsible for heart failure in a mouse model[J]. Int J Cardiol, 2017, 240:347-353.
[18] Wang L, Peng YF, Song LJ, et al. Colchicine-containing nanoparticles attenuates acute myocardial infarction injury by inhibiting inflammation[J]. Cardiovasc Drugs Ther, 2022, 36(6):1075-1089.
[19] Chen Y, Shi JY, Zhang YP, et al. An injectable thermosensitive hydrogel loaded with an ancient natural drug colchicine for myocardial repair after infarction[J]. Journal of Materials Chemistry B, 2020, 8(5):980-992.
[20] 凌浩, 刘明明, 于雪. 冠状动脉微血管功能障碍研究进展[J]. 国际心血管病杂志, 2022, 49(2):65-68.
[21] Li HQ, Yang HF, Qin ZB, et al. Colchicine ameliorates myocardial injury induced by coronary microembolization through suppressing pyroptosis via the AMPK/SIRT1/NLRP3 signaling pathway[J]. BMC Cardiovasc Disord, 2024, 24(1):23.
[22] Yu Y, Zhou M, Long X, et al. Study on the mechanism of action of colchicine in the treatment of coronary artery disease based on network pharmacology and molecular docking technology[J]. Front Pharmacol, 2023:1147360.
[23] Vaidya K, Arnott C, Martínez GJ, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a CT coronary angiography study[J]. JACC Cardiovasc Imaging, 2018, 11(2 Pt 2):305-316.
[24] Shah B, Toprover M, Crittenden DB, et al. Colchicine use and incident coronary artery disease in male patients with gout[J]. Can J Cardiol, 2020, 36(11):1722-1728.
[25] Crittenden DB, Lehmann RA, Schneck L, et al. Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout[J]. J Rheumatol, 2012, 39(7):1458-1464.
[26] Solomon DH, Liu CC, Kuo IH, et al. Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims[J]. Ann Rheum Dis, 2016, 75(9):1674-1679.
[27] Nidorf SM, Eikelboom JW, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease[J]. J Am Coll Cardiol, 2013, 61(4):404-410.
[28] Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease[J]. N Engl J Med, 2020, 383(19):1838-1847.
[29] Opstal TSJ, Fiolet ATL, van Broekhoven A, et al. Colchicine in patients with chronic coronary disease in relation to prior acute coronary syndrome[J]. J Am Coll Cardiol, 2021, 78(9):859-866.
[30] Mohammadnia N, Los J, Opstal TSJ, et al. Colchicine and diabetes in patients with chronic coronary artery disease:insights from the LoDoCo2 randomized controlled trial[J]. Front Cardiovasc Med, 2023, 10:1244529.
[31] Burger PM, Dorresteijn JAN, Fiolet ATL, et al. Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease[J]. Eur J Prev Cardiol, 2023, 30(18):1950-1962.
[32] Deftereos S, Giannopoulos G, Angelidis C, et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study[J]. Circulation, 2015, 132(15):1395-1403.
[33] Hennessy T, Soh L, Bowman M, et al. The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction[J]. Am Heart J, 2019, 215:62-69.
[34] Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial[J]. Circulation, 2020, 142(20):1890-1900.
[35] Mewton N, Roubille F, Bresson D, et al. Effect of colchicine on myocardial injury in acute myocardial infarction[J]. Circulation, 2021, 144(11):859-869.
[36] Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction[J]. N Engl J Med, 2019, 381(26):2497-2505.
[37] Roubille F, Bouabdallaoui N, Kouz S, et al. Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the colchicine cardiovascular outcomes trial (COLCOT)[J]. Diabetes Care, 2024, 47(3):467-470.
[38] Alexandrescu DM, Mitu O, Costache II, et al. Risk factors associated with intra-stent restenosis after percutaneous coronary intervention[J]. Exp Ther Med, 2021, 22(4):1141.
[39] Yu M, Zhu ZF, Yang F, et al. Different anti-inflammatory drugs on high-sensitivity C-reactive protein in patients after percutaneous coronary intervention: a pilot randomized clinical trial[J]. J Cardiovasc Pharmacol, 2024, 83(3):234-242.
[40] Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients[J]. J Am Coll Cardiol, 2013, 61(16):1679-1685.
[41] Correa-Sadouet C, Rodríguez-Granillo AM, Gallardo C, et al. Randomized comparison between bare-metal stent plus colchicine versus drug-eluting stent alone in prevention of clinical adverse events after percutaneous coronary intervention[J]. Future Cardiol, 2021, 17(4):539-547.
[42] Shah B, Pillinger M, Zhong H, et al. Effects of acute colchicine administration prior to percutaneous coronary intervention:COLCHICINE-PCI randomized trial[J]. Circ Cardiovasc Interv, 2020, 13(4):e008717.
[43] Cole J, Htun N, Lew R, et al. Colchicine to prevent periprocedural myocardial injury in percutaneous coronary intervention: the COPE-PCI pilot trial[J]. Circ Cardiovasc Interv, 2021, 14(5):e009992.
[44] Samuel M, Tardif JC, Bouabdallaoui N, et al. Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials[J]. Can J Cardiol, 2021, 37(5):776-785.
[45] Akl E, Sahami NZI, Labos C, et al. Meta-analysis of randomized trials: efficacy and safety of colchicine for secondary prevention of cardiovascular disease[J]. J Interv Cardiol, 2024, 2024:8646351.
[46] Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice[J]. Eur Heart J, 2021, 42(34):3227-3337.
[47] Miwa Y, Mutoh A, Morimoto T, et al. Effects of low-dose colchicine on serum high-sensitivity C-reactive protein level in coronary artery disease patients with type 2 diabetes mellitus and enhanced inflammatory response protocol for a randomized, double-blind, placebo-controlled, phase 2, dose-finding study[J]. Biomed Hub, 2022, 7(3):156-164.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（82104588）
通信作者：赵健，E-mail：drzhaojiansmmu@163.com
更新日期/Last Update: 2024-12-10